Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

Kristian Thidemann Andersen; Maja Hinge; Erik Kay Segel; Tina Ormstrup; Paw Holdgaard; Henrik Boel-Jørgensen; Niels Pallisgaard; Gitte Birk Kerndrup; Torben Plesner

Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Henrik Boel-Jørgensen, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner

Vejle Sygehus

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

Original language	English
Publication date	Sept 2015
Publication status	Published - Sept 2015
Event	15th International Myeloma Workshop (IMW) - Rome, Italy Duration: 23. Sept 2015 → 26. Sept 2015

Conference

Conference	15th International Myeloma Workshop (IMW)
Country/Territory	Italy
City	Rome
Period	23/09/2015 → 26/09/2015

Cite this

Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Boel-Jørgensen, H., Pallisgaard, N., Kerndrup, G. B., & Plesner, T. (2015). Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. Poster session presented at 15th International Myeloma Workshop (IMW), Rome, Italy.

@conference{b9c9fc5a83df46a38a8ac529fa19cda5,

title = "Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112",

author = "Andersen, {Kristian Thidemann} and Maja Hinge and Segel, {Erik Kay} and Tina Ormstrup and Paw Holdgaard and Henrik Boel-J{\o}rgensen and Niels Pallisgaard and Kerndrup, {Gitte Birk} and Torben Plesner",

year = "2015",

month = sep,

language = "English",

note = "15th International Myeloma Workshop (IMW) ; Conference date: 23-09-2015 Through 26-09-2015",

}

Andersen, KT, Hinge, M, Segel, EK, Ormstrup, T, Holdgaard, P, Boel-Jørgensen, H, Pallisgaard, N, Kerndrup, GB & Plesner, T 2015, 'Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112', 15th International Myeloma Workshop (IMW), Rome, Italy, 23/09/2015 - 26/09/2015.

Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. / Andersen, Kristian Thidemann; Hinge, Maja; Segel, Erik Kay et al.
2015. Poster session presented at 15th International Myeloma Workshop (IMW), Rome, Italy.

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

TY - CONF

T1 - Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112

AU - Andersen, Kristian Thidemann

AU - Hinge, Maja

AU - Segel, Erik Kay

AU - Ormstrup, Tina

AU - Holdgaard, Paw

AU - Boel-Jørgensen, Henrik

AU - Pallisgaard, Niels

AU - Kerndrup, Gitte Birk

AU - Plesner, Torben

PY - 2015/9

Y1 - 2015/9

M3 - Poster

T2 - 15th International Myeloma Workshop (IMW)

Y2 - 23 September 2015 through 26 September 2015

ER -

Andersen KT, Hinge M, Segel EK, Ormstrup T, Holdgaard P, Boel-Jørgensen H et al.. Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages. IMW 2015, PO-112. 2015. Poster session presented at 15th International Myeloma Workshop (IMW), Rome, Italy.